

Improving Outcomes in mCRC and GIST by Targeting Multiple Pathways

FACULTY

Axel Grothey, MD (Chair)
Mayo Clinic
Rochester, Minnesota, USA

Dirk Arnold, MD
Klinik für Tumorbiologie
University of Freiburg
Freiburg, Germany

George Demetri, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, USA

Salvatore Siena, MD
The Falck Division of Oncology
Ospedale Niguarda Ca' Granda
Milano, Italy

Friday, 26 September 2014
17.00 – 19.00

Oviedo Auditorium
IFEMA – Feria de Madrid
Madrid, Spain

AGENDA

- 17.00 – 17.05 Welcome and Introductions
Axel Grothey, MD
- 17.05 – 17.20 Where Are We Today? – Evidence-Based Medicine and the Evolving Treatment Paradigm in mCRC
Axel Grothey, MD
- 17.20 – 17.50 Applying Evidence-Based Medicine in Clinical Practice – A Case-Based Discussion on Third-Line Treatment of Colorectal Cancer
Dirk Arnold, MD
- 17.50 – 18.15 Evaluating mCRC Treatment Benefit in the Era of Targeted Therapies
Salvatore Siena, MD
- 18.15 – 18.45 Treatment of Progressive GIST – A Case-Based Discussion
George Demetri, MD
- 18.45 – 18.55 Panel Discussion – Practical Considerations for the New Era of Targeted Medicines
All
- 18.55 – 19.00 Conclusion/Symposium Recap
Axel Grothey, MD